Evidence supporting idarucizumab for the reversal of dabigatran.

Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers. Although elective invasive procedures and most bleeding complications in dabigatran-treated patients can be managed by temporarily stopping dabigatran therapy and using supportive measures, there are rare clinical situations that require urgent reversal of the anticoagulant effect of dabigatran. The effectiveness and safety of 5 g of intravenous idarucizumab is being investigated in a prospective, open-label, single-cohort study in patients with serious bleeding or in those requiring an urgent procedure. In an interim analysis of the first 90 participants, idarucizumab rapidly and completely reversed the anticoagulant activity of dabigatran in 88%-98% of participants, and there were no safety concerns, with no deaths or serious adverse events being attributable to idarucizumab. Supported by these interim results, idarucizumab has been approved in the United States and the European Union for use when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in patients with life-threatening or uncontrolled bleeding. Clinical use of idarucizumab should follow the same processes as patient enrollment in this study, which is projected to be completed in 2016. The outcomes achieved with this specific reversal agent are likely to be of continued interest to treating physicians

Final Equal Employment Opportunity Commission Rules on Retiree Health Plans and the Age Discrimination in Employment Act

CRS_April_2005_Final_EEOC_Rules_on_Retiree_Health_Plans.pdf: 417 downloads, before Oct. 1, 2020

Disparate Impact Analysis and the Age Discrimination in Employment Act: the Supreme Court Decision in Smith v. City of Jackson

CRS_April_2005_Disparate_Impact_and_ADEA.pdf: 16074 downloads, before Oct. 1, 2020

Sexual Harassment, Constructive Discharge, and Employers’ Affirmative Defenses: The U.S. Supreme Court Decision in Pennsylvania State Police v. Suders

CRS_June_2004_Sexual_Harassment_Constructive_Discharge_and_Employers_Affirmative_Defenses.pdf: 2660 downloads, before Oct. 1, 2020

IMPACT OF FEDERAL ACREAGE LIMITATION POLICY ON WESTERN IRRIGATED AGRICULTURE

Long-Run Average Cost Curves were developed for 18 Federal irrigation districts indicating in general constant cost industry. Conclusions were that InteriorÂ’s acreage limitation policy would cause no appreciable loss in economic efficiency nor an increase in food costs. Implementation of full-cost water pricing to recapture Federal subsidies would greatly reduce the amount of water demanded and significantly impact production of forages and other high water using crops.Land Economics/Use,

THE RECLAMATION REFORM ACT--P.E.S.T. OR PESTICIDE

Land Economics/Use,